Navigation Links
Successful Inspection by the FDA of ENCO Pharmaceutical Development's Cary, NC Facility

JACKSONVILLE, Fla., Feb. 19, 2013 /PRNewswire-iReach/ -- ENCO Pharmaceutical Development, Inc. (EPDI) is pleased to announce the completion of a successful FDA inspection of its Cary, NC facility.  The 3-day audit included both a general cGMP inspection as well as a directed Pre-approval Inspection (PAI).  This was the first FDA audit of EPDI's Cary facility which opened in 2010.

"We have worked hard over the years to ensure that our quality systems are robust and to foster an atmosphere of compliance within our organization," said Rick Camp , President of EPDI.   Christopher Walker , who manages the Cary facility commented, "It is gratifying to have completed this very thorough audit by the FDA so successfully, particularly since this is a new site for EPDI."

The audit covered thorough reviews of general systems and documentation such as SOP's, test methods and protocols and involved a variety of technical areas including analytical development, release and stability testing and storage.

Upon completion of the inspection, the investigator reported no findings and no Form 483 was issued.

ENCO Pharmaceutical Development Inc. provides a broad spectrum of pharmaceutical development and analytical services from its facilities in Jacksonville, FL and Cary, NC.  The company works with a variety of organizations in both the pharmaceutical and medical device industries, including global, small and mid-size firms, as well as virtual organizations. EPDI provides expertise in formulation development of solid, semi-solid, liquids, ophthalmic and lyophilized dosage forms as well as analytical support for method development and validation, stability studies, raw materials testing, extractable/leachable studies, medical device testing and more. For additional information, please visit

Media Contact: Keith Hurley , ENCO Pharmaceutical Development, Inc.,336-541-3270,

News distributed by PR Newswire iReach:

SOURCE ENCO Pharmaceutical Development, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
2. Columbia Asia Referral Hospital, Yeshwanthpur, Successfully Conducts HOLEP to Treat a 72-Year-old With Urology Disorder
3. Coyote Pharmaceuticals Initiates GMP Manufacturing Process for CNS-102 Following Successful Pre-IND Meeting
4. Kemwell Announces Successful Pre-NDA US FDA Inspection
5. New Study Introduces Valuable Tool to Aid Doctors and Patients in Choosing Successful Outcomes for Cheek Rejuvenation
6. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
7. Easy on the Stomach: ALCAT Worldwide Sponsors Successful Conference on Gut, Brain & Autoimmune Disorders
8. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
9. A Successful Launch of a New Oncology Product Requires Global Teams & Planning
10. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
11. Report Highlights Key Activities that Drive Successful New Product Planning Groups in Pharmaceutical Industry
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 Building on its ... & Johnson (NYSE: JNJ ) today announced ... Companies to significantly reduce the burden of HIV ... 74 percent of new HIV infections among adolescents ... AIDS Day, these new initiatives include collaborations with ...
(Date:12/1/2015)... 2015 ) ... Equipment and Disposables Market by product, by Animal ... their offering. --> ) has ... and Disposables Market by product, by Animal - ... offering. --> Research and Markets ( ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... Speech and physical therapies are traditionally conducted ... and under the right circumstances, these practices can be merged. This combination ... his or her therapeutic sessions, as well as gives the physical and speech ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is a ... number even greater among Millennials (a whopping one in three aged 18 to 25 ... who are dissatisfied with their ink. In fact, RealSelf , the world’s largest ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... everything. That is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch ... product in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President ...
(Date:12/1/2015)... Burlington, MA (PRWEB) , ... December 01, 2015 , ... ... the release of Clarity, the latest addition to the devices for sale in the ... technologies, 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , ... control over customization, the possibilities are truly endless, all with a click of a ... position, vertical flip, horizontal flip, depth of field and more, all within Final Cut ...
Breaking Medicine News(10 mins):